Monoclonal antibodies against IL-17A, such as Ixekizumab, Secukinumab, and Bimekizumab have been widely used clinically in immune-mediated inflammatory diseases such as psoriasis, psoriatic arthritis, and axial spondyloarthritis, showing high selectivity and safety [33–35]. Here, IL17A is linked to psoriasis.